Avidity Biosciences Completes $690 Million Share Offering
ByAinvest
Monday, Sep 15, 2025 4:22 pm ET1min read
RNA--
The company's expanding pipeline includes three clinical development programs. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE) [1]. AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial [1]. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial [1].
This latest funding round will support Avidity Biosciences' ongoing research and development efforts, particularly in advancing its pipeline of AOCs. The company aims to revolutionize the treatment landscape for rare and challenging diseases by leveraging the unique capabilities of its RNA therapeutics.
Avidity Biosciences has completed a $690 million share offering. The biopharmaceutical company is developing RNA therapeutics called antibody oligonucleotide conjugates (AOCs) to address previously unreachable targets and diseases. Its pipeline includes three clinical development programs: AOC 1001 for myotonic dystrophy type 1, AOC 1044 for Duchenne muscular dystrophy, and AOC 1020 for facioscapulohumeral muscular dystrophy.
Avidity Biosciences, Inc. has successfully completed a $690 million share offering. The biopharmaceutical company specializes in developing a new class of ribonucleic acid (RNA) therapeutics known as antibody oligonucleotide conjugates (AOCs). These AOCs combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling the treatment of previously unreachable targets and diseases.The company's expanding pipeline includes three clinical development programs. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE) [1]. AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial [1]. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial [1].
This latest funding round will support Avidity Biosciences' ongoing research and development efforts, particularly in advancing its pipeline of AOCs. The company aims to revolutionize the treatment landscape for rare and challenging diseases by leveraging the unique capabilities of its RNA therapeutics.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet